Curis Q1 operating loss widens as expenses rise

Curis

12/05/2026 21:11

Overview

Curis reported a Q1 net loss of $24.2 million, compared to a net loss of $10.6 million last year

Company posted no revenue after selling royalty rights in late 2025

Q1 net loss widened due to higher other expenses from PIPE financing warrant liability

Outlook

Curis says cash and expected warrant proceeds should fund operations into second half of 2027

Result Drivers

WARRANT LIABILITY - Higher other expenses in Q1 2026 were due to change in fair value of PIPE Financing warrant liability

PIPE FINANCING COSTS - General and administrative expenses rose due to costs associated with January 2026 PIPE Financing

NO REVENUE - Co reported no revenue in Q1 2026 after selling Erivedge royalty rights in Q4 2025

Company press release: ID:nPnbCRkcHa

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Net Income
-$24.20 mln
-$7.50 mln (2 Analysts)
Q1 Basic EPS
-$1.25
-$0.40 (2 Analysts)
Q1 Income From Operations
-$11.52 mln
-$8.02 mln (3 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Curis Inc is $17.00, about 2,985.3% above its May 11 closing price of $0.55

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)